scopolamine HBr — Competitive Intelligence Brief

scopolamine HBr (scopolamine HBr) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Neurology / Gastroenterology.

phase 3 Anticholinergic agent Muscarinic acetylcholine receptors (M1-M5) Neurology / Gastroenterology Small molecule

Target snapshot

scopolamine HBr (scopolamine HBr) — Repurposed Therapeutics, Inc.. Scopolamine HBr is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
scopolamine HBr TARGET	scopolamine HBr	Repurposed Therapeutics, Inc.	phase 3	Anticholinergic agent	Muscarinic acetylcholine receptors (M1-M5)
Neostigmine + Atropine	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Atropine Sulfate 0.04% Eye Drop	Atropine Sulfate 0.04% Eye Drop	Shanghai Eye Disease Prevention and Treatment Center	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1, M3, M5)
Transderm Scop®	Transderm Scop®	University of Iowa	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (non-selective antagonist)
Neostigmine with glycopyrrolate	Neostigmine with glycopyrrolate	The Cleveland Clinic	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase; muscarinic acetylcholine receptors
Solifenacin plus Tamsulosin	Solifenacin plus Tamsulosin	Soonchunhyang University Hospital	marketed	Anticholinergic agent + alpha-1A adrenergic antagonist combination	M3 muscarinic receptor; alpha-1A adrenergic receptor
Oxybutynin ER	Oxybutynin ER	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class